Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chloramine→

Chloramine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10599-90-3
Molecular formula
ClH2N
Molecular weight
51.47 g/mol
Drug class
Chlorine-releasing disinfectantinorganic antimicrobial oxidising agent
Mechanism of action
Releases active chlorine species that oxidise microbial proteins, enzymes and membrane components, resulting in broad-spectrum antimicrobial activity.
Indications / reported uses
  • Disinfection of water, surfaces and selected equipment using authorised chloramine formulations; not a therapeutic drug for systemic human infection

Sources: WHO — Guidelines for drinking-water quality: chloramine · PubChem — Chloramine · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Chlorine-releasing disinfectant; inorganic antimicrobial oxidising agent

Mechanism of action

Releases active chlorine species that oxidise microbial proteins, enzymes and membrane components, resulting in broad-spectrum antimicrobial activity.

General use cases

  • Disinfection of water, surfaces and selected equipment using authorised chloramine formulations; not a therapeutic drug for systemic human infection

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Chloramine Environmental Risk Assessment (ERA) (the Chloramine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.